|
| |
par-1
| Symbol: | par-1 | | Name(s): | par-1 | | Type: | protein-coding | | Organism: | Drosophila melanogaster | | Synonyms: | BcDNA:RH48823, CG11960, CG16701, CG30131, CG30132, CG8201, DPAR-1, DPar1, PAR1, anon-WO0210402.19, l(2)k06323 | | Links: |
Pubmed,
Entrez Gene,
Map Viewer.
|
Gene Information from Publications |
| Publication Link |
Summary of findings |
| 12176345 |
required for anterior-posterior axis formation in Drosophila |
| 11951092 |
Data indicate that posteriorly localized Par-1 regulates posterior patterning by stabilizing Osk. |
| 14675534 |
PAR-1 phosphorylates Bazooka/PAR-3 on two conserved serines to generate 14-3-3 binding sites. This inhibits formation of the Bazooka/PAR-6/aPKC complex by blocking Bazooka oligomerization and binding to aPKC. |
| 15006350 |
Data show that Drosophila PAR-1 kinase initiates tau toxicity by triggering a temporally ordered phosphorylation process. |
| 12225669 |
Through the combined actions of the fusome, MT, and Baz, Par-1 is selectively enriched and localized within the oocyte, where, in conjunction with BicD, Egalitarian (Egl), and Dynein, it acts on the MT cytoskeleton to effect polarization. |
| 12431373 |
Drosophila 14-3-3/PAR-5 is an essential mediator of PAR-1 function in axis formation. |
| 15694310 |
The spacer domain of PAR-1 is required for lateral plasma membrane localization of PAR-1 kinase and for development of a polarized follicular epithelium. |
| 15182702 |
The par-1 kinase plays a major role in the antero-posterier axis formation and germline determinants polarisation during oogenesis. |
| 15539486 |
Par-1 regulates bicoid mRNA localisation by phosphorylating Exuperantia |
| 16449319 |
a novel role for Par-1 in Notch signal transduction during embryonic neurogenesis and retina determination | →View more information from publications. |
Press Releases on par-1:
|
 |
| Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights |
19th November, 2009 |
Omeros Corporation |
-- Priced the Company's IPO on October 7, 2009, receiving net proceeds of
approximately $61.8 million, and began trading on The NASDAQ Global
Market under the ticker
|
| Shamir Optical Industry Ltd. Reports Third Quarter 2009 Results |
18th November, 2009 |
Shamir Optical Industries Ltd. |
KIBBUTZ SHAMIR, Israel, Nov. 18 /PRNewswire-FirstCall/ -- Shamir Optical Industry Ltd. (Nasdaq: SHMR) ("Shamir"), a leading provider of innovative products and
|
| Jiangbo Pharmaceuticals Announces First Quarter Fiscal Year 2010 Results |
17th November, 2009 |
Jiangbo Pharmaceuticals, Inc. |
LAIYANG, China, Nov. 17 /PRNewswire-Asia-FirstCall/ -- Jiangbo
Pharmaceuticals, Inc. (OTC Bulletin Board: JGBO) ("Jiangbo" or the "Company"),
a pharmaceutical company with
|
| Patient Safety Technologies Reports Third Quarter Results |
17th November, 2009 |
Patient Safety Technologies, Inc. |
TEMECULA, Calif., Nov. 17 /PRNewswire-FirstCall/ -- Patient Safety Technologies, Inc. (OTC Bulletin Board: PSTX) today announced third quarter 2009 results.
"We are
|
| Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update |
17th November, 2009 |
Neuralstem, Inc. |
ROCKVILLE, Md., Nov. 17 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) today provided a financial and business update for the third quarter ended September 30, 2009.
|
par-1 results (if any) from reagent suppliers | 
|
Search Bioportfolio and other Life Science Sites for par-1,
or search for par-1 on BioPortfolio's antibody search engine.
This page has been viewed 71 times
Recent Search Terms used to find this page: hep par-1 | .
Resources from the NCBI used on this page, NCBI's standard disclaimer applies.
|
